https://journals.sagepub.com/doi/full/10.1177/2514183X20925695
https://pubmed.ncbi.nlm.nih.gov/30383334/
Mirtazapine for treatment of visual snow syndrome: A case series with insights into pathophysiology and therapy
Ozan Eren, Christoph J SchankinFirst Published May 20, 2020 Research Article
https://doi.org/10.1177/2514183X20925695
Article information
Open AccessCreative Commons Attribution, Non Commercial 4.0 License
Article Information
Volume: 4 issue: 1,
Article first published online: May 20, 2020; Issue published: January 1, 2020
Ozan Eren1, Christoph J Schankin2
1Department of Neurology, Ludwig Maximilians University Munich, University Hospital – Großhadern, Munich, Germany
2Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, Bern, Switzerland
Corresponding Author:
Christoph J Schankin, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland. Email: christoph.schankin@insel.ch
Conclusion
VSS keeps it secrets, and there is still no ideal medical approach. The best data exist for lamotrigine, which therefore could be discussed off-label with patients. Despite VSS having high impact on patients’ mood, antidepressants do not seem to be a solution for the visual symptoms. VSS deserves more attention, and we encourage physicians to not only present medications helpful but also the ones being unsuccessful to avoid unnecessary trials in other patients.
